Search

everythinglearnresearchcommunity

for

Search:↓

Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.

MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.

Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.

A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.

Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.

TYK2 inhibitors show promise for treating cancer and autoimmune disorders.

BKN-1 antibody targets specific keratin in basal cell epithelioma and normal skin basal cells.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Ritlecitinib is safe and may effectively treat alopecia areata.

Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

The document concluded that certain compounds might strongly bind to and potentially inhibit a key SARS-CoV-2 protein, but further testing is needed.

New compounds were made that effectively block a specific enzyme related to androgen conditions.

RIPK1 inhibitors may help prevent alopecia areata by reducing immune cell activity.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.

Entospletinib effectively prevents eye and skin GVHD in mice.

Danoprevir, remdesivir, and saridegib may effectively inhibit SARS-CoV-2.

Rapamycin reduces skin cell growth and tumor development by affecting cell signaling in mice.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.

Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.

PRIDE complex side effects from EGFR inhibitors can be managed without stopping treatment.

Inhibiting TYK2 can restore hair growth in alopecia areata.

Normal cells outcompete and remove mutant cells in the pancreas with the help of the EphA2 receptor.

Lack of KSR1 stops certain skin tumors in mice.

Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.